Twitter | Search | |
Alex Friedlaender
Enjoying oncology, without meaning to sound too cynical
516
Tweets
15
Following
176
Followers
Tweets
Alex Friedlaender Jun 3
What will the role of chemo and abiraterone be if this becomes SOC? Potentially a huge game-changer...
Reply Retweet Like
Alex Friedlaender retweeted
Aditya Mandawat, MD Jun 2
Switched a patient from Ebarbyclor (Azilsartan/HCTZ; $166/mo) to Lisinopril/HCTZ ($4/mo). No change in BP, patients wallet significantly heavier. In the absence of RCTs showing a significant net clinical benefit, why do we allow these sorts of ‘designer drugs’ onto the market?
Reply Retweet Like
Alex Friedlaender retweeted
H. Jack West, MD Jun 1
Why are we seeing chaos & looting in US cities now? Because so many feel loss of control & system is unfair. I'd contend we should be thinking about this when we throw up our hands & say we, as oncologists, shouldn't be troubled w/insane cost of Rx that will be borne by society.
Reply Retweet Like
Alex Friedlaender May 31
This improved survival is also reinforced by the quality of life patients have on alectinib! I may be partial (it's a great name), but the ALEX trial remains my gold standard in ALK+
Reply Retweet Like
Alex Friedlaender retweeted
Dr. Antonio Calles 🌈😷 May 31
EVAN trial of adjuvant erlotinib in resected stage IIIA reported a 2yr DFS HR of 0.27. This is the closest HR to ADAURA. Does anyone know if OS data has been communicated anywhere? Patient accrual for the trial finished 5 ago, and we only have DFS data published.
Reply Retweet Like
Alex Friedlaender retweeted
Bishal Gyawali May 31
If you're testing Drug X v placebo and conclude that "OS benefit cannot be concluded due to a majority of patients in placebo arm getting the drug upon relapse", can I correct it and say "you don't need to give drug X upfront to all, we can give it at relapse with same effect"?
Reply Retweet Like
Alex Friedlaender May 31
We have to carefully look at the subsequent treatments given in these trials.
Reply Retweet Like
Alex Friedlaender retweeted
Dr. Antonio Calles 🌈😷 May 30
CTONG1104: 2-years adjuvant Gefitinib vs chemo in resected EGFR+ stage II-IIIA 👉 DFS HR 0.6 did not translate in OS gain. 👉 Subsequent treatments contribute to OS differences.
Reply Retweet Like
Alex Friedlaender May 30
I'm glad to hear other voices.
Reply Retweet Like
Alex Friedlaender retweeted
Giuseppe Banna May 30
And this was my post. He's not alone... 😉
Reply Retweet Like
Alex Friedlaender May 30
Reply Retweet Like
Alex Friedlaender May 30
Yes, I'm just shocked that we oncologists have become so complacent and just blindly swallow data.
Reply Retweet Like
Alex Friedlaender retweeted
Petros Tsantoulis May 30
Replying to @DralexGva
The rate of major cardiovascular events is also much more favorable, about half compared to leuprolide...
Reply Retweet Like
Alex Friedlaender May 30
Replying to @VPrasadMDMPH
Reminds me of ESMO conference 2 years ago at the presentation of apalutamide in non metastatic CRPC, the emphasis was on the PFS gain (including PSA): Rising PSA untreated vs rising PSA treated, of course the HR was huge. It was absurd and shameful to suggest it was a success.
Reply Retweet Like
Alex Friedlaender May 30
Yours is one of the few voices promoting common sense and EBM when it comes to this trial. Thanks! Adopting osi based on this evidence would set a very dangerous precedent! Thoughts ?
Reply Retweet Like
Alex Friedlaender May 30
Wise words of caution about adj EGFR...
Reply Retweet Like
Alex Friedlaender May 30
Great paper about BRAF muts in NSCLC! Read it, learn, enjoy! Thanks to all for the collaboration!
Reply Retweet Like
Alex Friedlaender May 30
This really looks promising as front-line androgen deprivation. If it becomes SOC, as it looks like it should, how would it impact the role of CT and abiraterone?
Reply Retweet Like
Alex Friedlaender retweeted
Petros Tsantoulis May 29
Reply Retweet Like
Alex Friedlaender May 28
Replying to @gbanna74
Not at all based on what I read... the control group is disastrous. The poor patients received successive anti-antidrogen drugs. Did I miss something? Chemo?
Reply Retweet Like